Cardiometabolic Diseases Market Scope And Analysis

  • Report Code : TIPRE00025374
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 293
Buy Now

Cardiometabolic Diseases Market Analysis Report 2022 to 2028

Buy Now

Cardiometabolic Diseases Market Report Cardiometabolic Diseases Market Size and Share Cardiometabolic Diseases Market Scope and Analysis

Cardiometabolic Diseases Market Report Scope

Report Attribute Details
Market size in 2021 US$ 93.49 Billion
Market Size by 2028 US$ 121.8 Billion
Global CAGR (2021 - 2028) 3.9%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Type
  • Cardiovascular Disease
  • Type 2 diabetes
  • Hypertension
  • Obesity
By Treatment
  • ACE Inhibitors
  • Diuretics
  • Glucophage
By Dosage
  • Tablet
  • Injection
By Route of Administration
  • Oral
  • Intravenous
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Eli Lilly and Company
  • Bayer AG
  • Arrowhead Pharmaceuticals Inc
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A S
  • AstraZeneca
  • Alnylam Pharmaceuticals Inc
  • Cardax Inc

    •  

    Company Profiles

    • Eli Lilly and Company
    • Bayer AG
    • Arrowhead Pharmaceuticals, Inc
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Novo Nordisk A/S
    • AstraZeneca
    • Alnylam Pharmaceuticals, Inc.
    • Cardax, Inc
    • Kowa Company, Ltd.